DEFINITION

An oral Janus kinase (JAK) inhibitor that primarily inhibits JAK1 and JAK3 (with lesser activity against JAK2), thereby suppressing multiple cytokine signaling pathways involved in immune-mediated inflammatory diseases.

MECHANISM OF ACTION

Cytokines that drive various inflammatory diseases (such as rheumatoid arthritis, psoriasis, and alopecia areata) signal through the JAK-STAT pathway, where Janus kinases (JAKs) inside the cell activate STAT proteins that then turn on inflammatory genes in the nucleus.

Tofacitinib is an oral small-molecule JAK inhibitor, but unlike upadacitinib which is selective for JAK1, tofacitinib is a pan-JAK inhibitor with predominant activity against JAK1 and JAK3, and weaker activity against JAK2. By inhibiting JAK1 and JAK3, tofacitinib blocks the signaling of common gamma chain cytokines such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, as well as JAK1-dependent cytokines like IL-6 and interferons.

This broader inhibition of multiple JAK isoforms leads to suppression of both innate and adaptive immune responses, including T-cell activation and proliferation. In rheumatoid arthritis, the primary approved indication, tofacitinib reduces synovial inflammation and joint destruction by blocking IL-6 and other pro-inflammatory cytokines.

However, because tofacitinib also inhibits JAK2 at therapeutic doses, it can cause cytopenias (anemia, neutropenia, thrombocytopenia) by interfering with erythropoietin and thrombopoietin signaling, a side effect not typically seen with JAK1-selective inhibitors.

The drug is administered orally and has a relatively rapid onset of action, similar to other JAK inhibitors. Compared to dupilumab, tofacitinib has a much broader immunosuppressive profile and carries boxed warnings for serious infections, thrombosis, malignancy, and major adverse cardiovascular events.

• Inhibits

  • JAK1

  • JAK3

  • Partial inhibition of JAK2

• Blocks signaling of cytokines utilizing the JAK–STAT pathway, especially:

  • IL-2

  • IL-4

  • IL-6

  • IL-7

  • IL-15

  • IL-21

  • IFN-γ

Result:

• ↓ T-cell activation

• ↓ inflammatory cytokine signaling

• ↓ immune-mediated inflammation

PATHOPHYSIOLOGICAL RATIONALE

• Many inflammatory dermatoses are driven by cytokines signaling through JAK–STAT pathways

• Tofacitinib broadly suppresses these intracellular pathways

• Less selective than Upadacitinib → broader immunomodulatory effects

DERMATOLOGICAL INDICATIONS

Important uses:

• Alopecia areata (major exam association)

• Vitiligo (off-label)

• Atopic dermatitis (less central than newer JAK inhibitors)

Systemic indications:

• Rheumatoid arthritis

• Psoriatic arthritis

• Ulcerative colitis

ALOPECIA AREATA (VERY HIGH-YIELD)

Why effective?

• Alopecia areata is mediated by:

  • CD8+ T cells

  • IFN-γ signaling

• IFN-γ pathway depends on JAK signaling

→ Tofacitinib suppresses autoimmune attack on hair follicles

DOSING

• Oral administration

• Usually twice daily dosing (classic formulation)

ADVERSE EFFECTS (VERY HIGH-YIELD)

Common:

• Upper respiratory infections

• Headache

• Acne

• GI upset

Serious:

1. Infections

• Herpes zoster (important exam point)

• Opportunistic infections

• Tuberculosis reactivation

2. Hematologic abnormalities

• Anemia

• Neutropenia

• Lymphopenia

3. Lipid elevation

• ↑ LDL and HDL

4. Thromboembolism

• DVT / pulmonary embolism

5. Major adverse cardiovascular events (MACE)

6. Malignancy risk

• Long-term concern

MONITORING (EXAM-IMPORTANT)

Before treatment:

• CBC

• LFTs

• Lipid profile

• TB screening

• Hepatitis screening

During therapy:

• Repeat CBC, LFTs, lipids periodically

CONTRAINDICATIONS / CAUTIONS

• Active infection

• Severe hepatic impairment

• History of thromboembolism (relative caution)

COMPARISON WITH OTHER JAK INHIBITORS

Tofacitinib:

• JAK1/JAK3 predominant

• Less selective

• Broader immunosuppression

Upadacitinib:

• More JAK1 selective

• Better efficacy in atopic dermatitis

• Faster itch reduction

EXAM-FOCUSED INSIGHTS

• JAK1/JAK3 inhibitor

• Strong association with alopecia areata

• Broad intracellular cytokine suppression

• Risk of:

  • Herpes zoster

  • Thrombosis

  • Lab abnormalities

• Requires routine laboratory monitoring

MUST-KNOW QUESTIONS

1. What is the primary molecular target of tofacitinib, and how does it differ from upadacitinib?

Answer: Tofacitinib is a pan-JAK inhibitor with predominant inhibition of JAK1 and JAK3 (and weaker JAK2 inhibition). Upadacitinib is selective for JAK1. This difference explains tofacitinib's broader immunosuppression and JAK2-related cytopenias.

2. In which dermatologic condition is tofacitinib FDA-approved, and what is its route of administration?

Answer: Tofacitinib is FDA-approved for moderate-to-severe alopecia areata (in addition to rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis). It is administered orally (typically 5 mg twice daily or 10 mg twice daily for alopecia areata).

3. A patient on tofacitinib develops new-onset anemia and thrombocytopenia. Inhibition of which JAK isoform is most likely responsible?

Answer: JAK2 inhibition. JAK2 mediates signaling of erythropoietin (red blood cell production) and thrombopoietin (platelet production). Tofacitinib's weak but clinically relevant JAK2 blockade causes cytopenias, whereas JAK1-selective inhibitors (upadacitinib, abrocitinib) do not.

4. Name three serious boxed warnings (black box warnings) associated with tofacitinib.

Answer:

1. Serious infections (including tuberculosis, herpes zoster, opportunistic infections)

2. Malignancy (lymphoma, lung cancer)

3. Major adverse cardiovascular events (MACE) and thromboembolism (DVT/PE)
   *(Also acceptable: All-cause mortality in patients over 50 with cardiovascular risk factors)*

5. A 60-year-old with rheumatoid arthritis and a history of deep vein thrombosis asks about tofacitinib for alopecia areata. Is this safe?

Answer: No. Tofacitinib carries a boxed warning for thromboembolism (DVT and PE) , especially in patients with prior thromboembolic events. This is a relative to absolute contraindication. A safer alternative would be a JAK1-selective inhibitor (if needed) or non-JAK therapy.

6. How does tofacitinib compare with upadacitinib regarding herpes zoster risk, and why?

Answer: Tofacitinib has a higher risk of herpes zoster compared to upadacitinib. Tofacitinib's broader JAK1/JAK3 inhibition (and partial JAK2) causes greater suppression of T-cell and NK-cell function, impairing varicella-zoster virus surveillance more profoundly than selective JAK1 inhibition.

7. A patient starting tofacitinib has a positive PPD (tuberculosis skin test) but no symptoms. What must be done before initiating therapy?

Answer: Treatment for latent tuberculosis (e.g., isoniazid for 9 months or rifampin for 4 months) must be completed before starting tofacitinib. Tofacitinib can reactivate latent TB because it broadly suppresses IFN-γ and other anti-mycobacterial immune pathways.

8. What baseline and monitoring labs are required for a patient on tofacitinib?

Answer:

• Baseline: CBC, LFTs, lipid panel, serum creatinine, TB screening, hepatitis B/C serologies

• Monitoring: CBC every 3 months (for cytopenias), LFTs every 3–6 months, lipids at 4–8 weeks then every 3–6 months, and periodic infection surveillance

9. A dermatologist considers tofacitinib for psoriasis. Is this an FDA-approved indication, and if not, what JAK inhibitor is approved for psoriasis?

Answer: No, tofacitinib is not FDA-approved for plaque psoriasis (though used off-label). The only JAK inhibitor approved for psoriasis is deucravacitinib (TYK2 inhibitor, not a JAK inhibitor). For psoriatic arthritis, tofacitinib and upadacitinib are approved.

10. Why is tofacitinib preferred over upadacitinib for alopecia areata, despite similar efficacy?

Answer: Tofacitinib has longer and broader clinical experience in alopecia areata, and the JAK1/JAK3 dual inhibition (blocking IL-15 and IFN-γ) may be particularly effective in disrupting the CD8+ NKG2D+ T-cell attack on hair follicles. However, upadacitinib is also effective and approved for alopecia areata, but tofacitinib remains commonly used due to earlier approval and lower cost in some settings.